Attention:
Card image cap

Production Restraints During the Pandemic: Understanding Farm Cooperatives and the Capper-Volstead Act


Level: Advanced
Runtime: 94 minutes
Recorded Date: November 19, 2021
Click here to share this program
Printer-Friendly Version
Closed Caption

Agenda

  • History and requirements
  • Application in practice
  • Tips for compliance
Runtime: 1 hour, 34 minutes
Recorded: November 19, 2021

For NY - Difficulty Level: For experienced attorneys only (non-transitional)
For NY - Difficulty Level: Experienced attorneys only (non-transitional)

Description

The COVID-19 pandemic has been disruptive for the U.S. agricultural system with broad and varying impacts on farmers. The disrupted agriculture supply chains caused many farmers to work collaboratively in an effort to pool their produce and resources. Although cooperative structures have helped small farmers, these adaptations have been met with many looming challenges.

Join seasoned attorneys as they discuss the history and scope of the Capper-Volstead Act, outline risks that farm cooperatives face despite the exemption, and provide best practices for representing clients who are involved in farm cooperatives or are farm cooperatives.

This program was recorded on November 19th, 2021.

Provided By

American Bar Association
Card image cap

Panelists

Card image cap

Luke Hasskamp

Partner
Bona Law

Luke has litigated antitrust as well as class action and civil RICO matters. Luke has deep experience in all phases of litigation, from initial dispositive motions, through discovery, trial, and appeal. His experience includes federal and state litigation as well as administrative proceedings and arbitration. Luke also has significant federal appellate experience having briefed and argued numerous matters before state and federal appellate courts, and he has represented clients in government investigations.

Following law school, Luke clerked for three federal judges: Kermit E. Bye of the Eighth Circuit, Manuel L. Real of the Central District of California, and Robert G. James of the Western District of Louisiana. After completing his clerkship on the Eighth Circuit, Luke moved to private practice, working for Kanner & Whiteley in New Orleans, Louisiana, and Robins Kaplan in Minneapolis, Minnesota before joining Bona Law as a partner. He also served as special counsel for the Louisiana’s Attorney General in healthcare litigation involving the State of Louisiana.

Luke believes his experience as a litigator and trial lawyer benefits all areas of his practice by bringing a disciplined focus on the relevant issues and facts from the early stages of any matter. This focus leads not only to the most effective, but also efficient, resolution of the problem his client is facing.

Card image cap

Aaron Gott

Partner & Chief Operating Officer
Bona Law

Aaron Gott is a top-rated antitrust lawyer who focuses on antitrust and competition litigation, complex business litigation, challenges to government conduct, and appeals. Aaron has represented clients in dozens of antitrust cases, and served as lead counsel in a number of them, including: FTC v Qualcomm, In re Disposable Contact Lens Antitrust Litigation, In re Capacitors Litigation, Salt River Agricultural Improvement District v. Tesla Energy, and North Carolina State Board of Dental Examiners v. FTC (see representative matters for a more complete list). He has represented several parties before the U.S. Supreme Court and argued countless appeals in the U.S. Courts of Appeals. He is also one of the nation’s leading lawyers on issues involving antitrust federalism and the state-action immunity. He counsels clients on a range of issues, including antitrust compliance, antitrust exemptions including farm cooperatives under the Capper-Volstead Act, and employment noncompete agreements.

Aaron is a combat veteran who served nearly a decade in the U.S. Army. He entered law school with over five years of professional writing experience as a newspaper editor and Army public affairs officer. His work has been published in newspapers throughout the country, trade magazines, academic journals, and government publications; he has received accolades from general officers, scholars, high-profile litigators, and even federal judges. Aaron’s legal scholarship has been called “meticulously researched and brilliantly argued,” and showcased as “rigorous and elegant writing.”


Card image cap

Similar Courses

Card image cap
60 minutes
60 Consumer Tips in 60 Minutes
This panel of national consumer experts will provide you with the necessary tips for achieving great results in your consumer cases.

American Bankruptcy Institute

$75

Add to Cart
Card image cap
77 minutes
A Catch-22: Dilemmas for Landlords in the Era of COVID-19
This panel will explore the myriad legal conundrums landlords have been facing in bankruptcy cases across the country since the COVID-19 pandemic took hold. Discussion points will include landlord rights to assumption/rejection and timing, the ability of debtors to defer rent payments to landlords for lengthy periods of time, and the impact of force majeure clauses in these disputes.

American Bankruptcy Institute

$95

Add to Cart
Card image cap
60 minutes
ABI’s Commission on Consumer Bankruptcy vs. the Consumer Bankruptcy Reform Act
This panel will compare Sen. Elizabeth Warren’s bill with the ABI Consumer Commission’s Final Report, released in 2019, and will address consumer bankruptcy legislation that could be introduced this spring.

American Bankruptcy Institute

$75

Add to Cart
Card image cap
74 minutes
Anatomy of a Pharmaceutical Bankruptcy Case
This panel will present a primer on the U.S. pharmaceutical industry, focusing on the typical capital structures of pharmaceutical/development companies versus in-pipeline companies. The panelists will examine the factors leading to the recent surge in pharmaceutical bankruptcy cases and their outcomes/resolutions, as well as ? 363 sales of pharmaceutical companies’ assets and restructurings. Opiate bankruptcy cases such as Purdue and Mallinckrodt will be highlighted, as will ancillary issues that arise in pharmaceutical bankruptcy cases, such as product recalls, regulatory issues (such as with the FDA) and IP licensing issues.

American Bankruptcy Institute

$95

Add to Cart
Previous Next